| Bioactivity | Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1][2]. |
| Invitro | Romlusevimab 和 Amubarvimab (HY-P99435) 结合 SARS-CoV-2 刺突蛋白的不同表位[1]。Romlusevimab 与 Amubarvimab 联合使用时具有累加效应[1] 。 |
| In Vivo | Romlusevimab (10 mg/kg，ip，单次)与 Amubarvimab (HY-P99435) 联合使用可在 SARS-CoV-2 感染小鼠模型中保护动物免受 Omicron 感染[1]。 |
| Name | Romlusevimab |
| CAS | 2509447-08-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82(12):1327-1331. [2]. Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435. |